Intranasal medication delivery is important for both specifically developed pharmaceutical drugs designed for intranasal treatment, as well as for investigating off label uses of commonly available generic medications. Nasal sprays for local effect are quite common. Steroids, antiasthma medications such as salbutamol, ipratropium, montelukast and a large number of inhalational anaesthetic agents are being commonly used. Increase in the incidence of chronic obstructive pulmonary disease, asthma, and other fatal respiratory disorders are driving the global inhalation and nasal spray generic drugs market.
The global inhalation and nasal spray generic drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the indication type (allergic rhinitis, asthma, COPD, etc.), therapeutic drug classes (antihistamines, bronchodilators – albuterol, epinephrine; combination drugs – Azelastine (benzalkonium chloride), Formoterol (budesonide), Salmeterol (fluticasone); Corticosteroids – beclomethasone, budesonide, flunisolide, fluticasone; decongestant sprays – phenylephrine and oxymetazoline hydrochlorides), and forecasts growth trends (CAGR% – 2017 to 2021).
The global inhalation and nasal spray generic drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global inhalation and nasal spray generic drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global inhalation and nasal spray generic drugs market and included in this report are Teva Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Allergan plc, Mylan N.V., Ranbaxy Laboraotries Ltd., Roxane Laboratories, Inc., Beximco Pharmaceuticals Ltd., Cipla Ltd., and Nephron Pharmaceuticals Corporation.